Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03971734 · ClinicalTrials.gov registry record · Phase 1
Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT03971734 is a Phase 1 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 7 participants.
The verdict
NCT03971734, a Phase 1 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
enroll patients with histologically confirmed high-grade gliomas to evaluate the ability of regadenoson to transiently disrupt a relatively intact blood-brain barrier (BBB). determine the best dose of regadenoson to disrupt the BBB and allow for enhanced penetration of gadolinium during MRI.
Interventions
- DRUG Regadenoson 0.05mg
- DRUG Regadensoson 0.1mg
- DRUG Regadensoson 0.2mg
- DRUG Regadensoson 0.4mg
- DRUG Regadensoson 0.7mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2019-12-06 |
| Est. Completion | 2023-10-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03971734
The ClinicalTrials.gov registry entry for NCT03971734 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Regadenoson 0.05mg is the first listed.
NCT03971734 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03971734 about?
NCT03971734 is a clinical study titled "Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas". enroll patients with histologically confirmed high-grade gliomas to evaluate the ability of regadenoson to transiently disrupt a relatively intact blood-brain barrier (BBB). determine the best dose of regadenoson to disrupt the BBB and allow for enhanced penetration of gadolinium during MRI.
What is the current status of trial NCT03971734?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2019-12-06. Estimated completion is 2023-10-02.
What interventions are being tested in trial NCT03971734?
The interventions under investigation include: Regadenoson 0.05mg (DRUG), Regadensoson 0.1mg (DRUG), Regadensoson 0.2mg (DRUG), Regadensoson 0.4mg (DRUG), Regadensoson 0.7mg (DRUG).
Who is sponsoring clinical trial NCT03971734?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.